归创通桥(02190)发布公告，于2025年8月26日斥资118.1万港元回购5万股股份。 ...

智通财经APP讯，归创通桥(02190)发布公告，于2025年8月26日斥资118.1万港元回购5万股股份。 ...

公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年8月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總 ...

Summary of Key Points Core Viewpoint - On August 25, nine Hong Kong-listed companies conducted share buybacks, totaling 1.8064 million shares and an aggregate amount of HKD 577 million [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 895,000 shares for HKD 551 million, with a highest price of HKD 620.00 and a lowest price of HKD 608.50, bringing its total buyback amount for the year to HKD 43.347 billion [1][2]. - Hang Seng Bank repurchased 200,000 shares for HKD 22.697 million, with a highest price of HKD 113.90 and a lowest price of HKD 112.70, totaling HKD 38.606 million for the year [1][2]. - Beisen Holdings repurchased 200,000 shares for HKD 1.5988 million, with a highest price of HKD 8.09 and a lowest price of HKD 7.86, totaling HKD 34.2558 million for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on August 25 was from Tencent Holdings at HKD 551 million, followed by Hang Seng Bank at HKD 22.697 million [1][2]. - In terms of buyback volume, Tencent Holdings led with 895,000 shares, followed by Qinqin Food at 320,000 shares and Beisen Holdings at 200,000 shares [1][2]. Group 3: Notable Events - Qinqin Food's buyback on this date marked its first buyback of the year, while Tencent Holdings has conducted multiple buybacks totaling HKD 43.347 billion for the year [2].

Group 1 - Business Development (BD) is a significant trend in the domestic medical device industry, with a notable increase in BD transactions for innovative drugs, reaching a total of $60.8 billion in the first half of the year, surpassing the total for 2024 [1] - The Chinese government is promoting the development of domestic medical devices, with a focus on high-end medical equipment and technologies such as medical robots and AI medical devices, as outlined in the announcement released in July 2025 [2] - There is a fundamental difference in the evaluation systems and investment models between innovative drugs and medical devices, with medical devices requiring more extensive market and academic investment for recognition in different markets [3] Group 2 - The current BD model for medical devices is not suitable for a simple license-out approach due to the high dependency on usage scenarios and the experience of practitioners, which complicates the management and control of subsequent clinical trials and registrations [4] - Although the current BD model for innovative drugs may not fit medical devices, there are still BD transactions occurring in the medical device sector, such as the joint venture established between China Medical Device Co., Ltd. and GE Healthcare China [5] - The recently published "Medical Device BD White Paper 2025" indicates that BD in the medical device sector encompasses various transaction activities, including technology licensing, joint development, and strategic investments, with a focus on the actual product deployment [6] Group 3 - The trend in medical device BD is shifting from single transactions to a more structured resource allocation system, with an increasing willingness among investors and partners to engage in the early stages of product development and registration [7]

Group 1 - The company, Guichuang Tongqiao, repurchased 50,000 shares at an average price of HKD 23.68 per share, totaling approximately HKD 1.1842 million, with a cumulative repurchase of 4.1145 million shares this year, representing 1.29% of the total share capital [1] - The recent stock repurchase activity may indicate management's confidence in the company's future development and belief that the current stock price is undervalued [1] - Stock buybacks are often viewed as a positive signal, potentially reducing the number of shares in circulation, thereby enhancing earnings per share and stock price [1] Group 2 - Guichuang Tongqiao is an innovative medical device company listed on the Hong Kong Stock Exchange, focusing on the research, production, and sales of peripheral vascular interventional medical devices [2] - The company aims to provide high-quality and innovative medical solutions, with products including balloon dilation catheters and stents, capturing a certain market share in the growing medical device industry [2] - The business development of Guichuang Tongqiao is closely linked to the increasing global demand for medical services, particularly in light of the rising attention to vascular diseases, indicating a broad market prospect for its products [2]

智通财经APP讯，归创通桥(02190)发布公告，于2025年8月25日，该公司斥资118.42万港元回购5万股。 ...

格隆汇8月25日丨归创通桥(02190.HK)公告，8月25日耗资118万港元回购5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年8月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Insights - The neurointervention sector has undergone significant changes since the implementation of centralized procurement in 2021, leading to increased investment interest in domestic medical devices with low localization rates [1][2] - Domestic companies like Guichuang Tongqiao have shown strong performance in centralized procurement, with revenue growth of 31.7% and net profit growth of 76% in the first half of the year [1][2] - The market is characterized by a high proportion of imported brands, with 80% in the neurovascular intervention market and 85% in the peripheral vascular intervention market [1][2] Group 1: Market Dynamics - Centralized procurement has become a critical turning point for the pharmaceutical industry, with some leading companies losing market share while others capitalize on procurement opportunities [2][3] - Guichuang Tongqiao's core business in neurovascular and peripheral vascular intervention products saw sales growth of 25.0% and 46.2% respectively [2][3] - The average price drop for products in centralized procurement ranges from 10% to 25%, with specific products like spring coils seeing a price reduction from 12,000 yuan to a minimum of 3,277 yuan [2][3] Group 2: Future Trends - The trend towards domestic production and the strengthening of leading domestic companies is expected to continue, with improved gross and net profit margins anticipated for companies [3][5] - The National Medical Insurance Administration is optimizing procurement rules, which may lead to more reasonable pricing strategies among companies [3][5] - The volume of neurointervention surgeries is expected to grow, supported by the implementation of DRG 2.0 pricing regulations and the anticipated increase in usage of drug balloons following the upcoming sixth batch of national procurement [4][5] Group 3: Company Performance - Guichuang Tongqiao has set a net profit guidance of 150 million yuan for 2025, having already achieved 120 million yuan in the first half of the year [5] - The company remains confident in exceeding its previous annual profit expectations, despite anticipating higher expenses in the second half of the year [5]